HomeCompareNPPNY vs MAIN

NPPNY vs MAIN: Dividend Comparison 2026

NPPNY yields 2.84% · MAIN yields 7.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAIN wins by $47.79M in total portfolio value
10 years
NPPNY
NPPNY
● Live price
2.84%
Share price
$7.40
Annual div
$0.21
5Y div CAGR
47.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$158.3K
Annual income
$65,881.22
Full NPPNY calculator →
MAIN
Main Street Capital Corporation
● Live price
7.09%
Share price
$51.65
Annual div
$3.66
5Y div CAGR
72.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.95M
Annual income
$40,208,699.11
Full MAIN calculator →

Portfolio growth — NPPNY vs MAIN

📍 MAIN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNPPNYMAIN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NPPNY + MAIN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NPPNY pays
MAIN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NPPNY
Annual income on $10K today (after 15% tax)
$241.22/yr
After 10yr DRIP, annual income (after tax)
$55,999.04/yr
MAIN
Annual income on $10K today (after 15% tax)
$602.32/yr
After 10yr DRIP, annual income (after tax)
$34,177,394.24/yr
At 15% tax rate, MAIN beats the other by $34,121,395.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NPPNY + MAIN for your $10,000?

NPPNY: 50%MAIN: 50%
100% MAIN50/50100% NPPNY
Portfolio after 10yr
$24.05M
Annual income
$20,137,290.17/yr
Blended yield
83.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MAIN right now

NPPNY
No analyst data
Altman Z
6.7
Piotroski
5/9
MAIN
Analyst Ratings
2
Buy
11
Hold
Consensus: Hold
Price Target
$65.25
+26.3% upside vs current
Range: $60.00 — $70.00
Altman Z
1.7
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NPPNY buys
0
MAIN buys
0
No recent congressional trades found for NPPNY or MAIN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNPPNYMAIN
Forward yield2.84%7.09%
Annual dividend / share$0.21$3.66
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR47.7%72.7%
Portfolio after 10y$158.3K$47.95M
Annual income after 10y$65,881.22$40,208,699.11
Total dividends collected$128.1K$46.82M
Payment frequencyquarterlymonthly
SectorStockBDC

Year-by-year: NPPNY vs MAIN ($10,000, DRIP)

YearNPPNY PortfolioNPPNY Income/yrMAIN PortfolioMAIN Income/yrGap
1← crossover$11,119$419.15$12,464$1,223.78$1.3KMAIN
2$12,541$643.33$16,353$2,343.58$3.8KMAIN
3$14,420$1,001.58$23,105$4,724.42$8.7KMAIN
4$17,019$1,589.76$36,226$10,256.23$19.2KMAIN
5$20,801$2,590.00$65,426$24,707.64$44.6KMAIN
6$26,626$4,369.50$142,101$68,562.02$115.5KMAIN
7$36,211$7,720.76$388,521$228,799.95$352.3KMAIN
8$53,240$14,493.90$1,397,868$961,169.80$1.34MMAIN
9$86,382$29,415.55$6,884,663$5,313,459.69$6.80MMAIN
10$158,310$65,881.22$47,947,060$40,208,699.11$47.79MMAIN

NPPNY vs MAIN: Complete Analysis 2026

NPPNYStock

Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.

Full NPPNY Calculator →

MAINBDC

Main Street Capital Corporation is a business development company specializes in equity capital to lower middle market companies. The firm specializing in recapitalizations, management buyouts, refinancing, family estate planning, management buyouts, refinancing, industry consolidation, mature, later stage emerging growth. The firm also provides debt capital to middle market companies for acquisitions, management buyouts, growth financings, recapitalizations and refinancing. The firm seeks to partner with entrepreneurs, business owners and management teams and generally provides one stop financing alternatives within its lower middle market portfolio. It prefers to invest in air freight and logistics, auto components, building products, chemicals, commercial services, computers, construction and engineering, consumer finance, consumer services, electronic equipment, energy equipment and services, financial services, health care equipment, health care providers, hotels, restaurants, and leisure, internet software and services, IT Services, machinery, oil, gas and consumable fuels, paper and forest products, professional and industrial services, road and rail, software, specialty retail, telecommunication, consumer discretionary, energy, materials, technology, and transportation. The firm typically invests in lower middle market companies generally with annual revenues between $5 million and $300 million. It prefers to invest in ranging between $2 million and $75 million in equity investment and enterprise value in ranging between $3 million and $20 million. The firm typically prefers to invest in the range of $5 million and $50 million per transaction in debt investment value and in the range of $1 million and $20 million in annual EBITDA. The firm's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies. It takes 5 percent minority and up to 50 percent majority equity investments. Main Street Capital Corporation was founded in 2007 and is based in Houston, Texas with an additional office in Chojnów, Poland.

Full MAIN Calculator →
📬

Get this NPPNY vs MAIN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NPPNY vs SCHDNPPNY vs JEPINPPNY vs ONPPNY vs KONPPNY vs ARCCNPPNY vs HTGCNPPNY vs GBDCNPPNY vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.